VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q114339983 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241120235725.0
008 241120nneanz||abbn n and d
035 ‎‡a (WKP)Q114339983‏
035 ‎‡a (OCoLC)Q114339983‏
100 0 ‎‡a Egbert F. Smit‏ ‎‡9 ast‏
400 0 ‎‡a Egbert F Smit‏ ‎‡c researcher‏ ‎‡9 en‏
670 ‎‡a Author's A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer‏
670 ‎‡a Author's Absolute Quantification of [11C]docetaxel Kinetics in Lung Cancer Patients Using Positron Emission Tomography‏
670 ‎‡a Author's An 82-year-old woman with small-cell lung cancer: relapse after 9 years or a new primary?‏
670 ‎‡a Author's Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer.‏
670 ‎‡a Author's Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.‏
670 ‎‡a Author's Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients‏
670 ‎‡a Author's Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions.‏
670 ‎‡a Author's Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus‏
670 ‎‡a Author's Cost-Utility of Stepped Care Targeting Psychological Distress in Patients With Head and Neck or Lung Cancer.‏
670 ‎‡a Author's Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy.‏
670 ‎‡a Author's Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.‏
670 ‎‡a Author's DNA copy number aberrations in endobronchial lesions: a validated predictor for cancer‏
670 ‎‡a Author's Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity‏
670 ‎‡a Author's Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [‏
670 ‎‡a Author's Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.‏
670 ‎‡a Author's Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC.‏
670 ‎‡a Author's EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study‏
670 ‎‡a Author's Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies‏
670 ‎‡a Author's Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids‏
670 ‎‡a Author's Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?‏
670 ‎‡a Author's Long-term expanding human airway organoids for disease modeling‏
670 ‎‡a Author's Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis‏
670 ‎‡a Author's Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer‏
670 ‎‡a Author's Negative NKX2-1‏
670 ‎‡a Author's Negative NKX2-1 (TTF-1) as Temporary Surrogate Marker for Treatment Selection During EGFR-Mutation Analysis in Patients with Non–Small-Cell Lung Cancer‏
670 ‎‡a Author's Parametric methods for quantification of 18F-FAZA kinetics in non-small cell lung cancer patients‏
670 ‎‡a Author's Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients.‏
670 ‎‡a Author's Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer.‏
670 ‎‡a Author's Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction‏
670 ‎‡a Author's Quantitative and Simplified Analysis of 11C-Erlotinib Studies‏
670 ‎‡a Author's Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.‏
670 ‎‡a Author's Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography‏
670 ‎‡a Author's Reproducibility of tumor perfusion measurements using 15O-labeled water and PET.‏
670 ‎‡a Author's Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report‏
670 ‎‡a Author's Stepped care targeting psychological distress in head and neck and lung cancer patients: a randomized clinical trial‏
670 ‎‡a Author's Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: which groups specifically benefit? Secondary analyses of a randomized controlled trial‏
670 ‎‡a Author's Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography.‏
919 ‎‡a closesurveillancewithlongtermfollowupofsubjectswithpreinvasiveendobronchiallesions‏ ‎‡A Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions.‏ ‎‡9 1‏
919 ‎‡a 82yearoldwomanwithsmallcelllungcancerrelapseafter9yearsoranewprimary‏ ‎‡A An 82-year-old woman with small-cell lung cancer: relapse after 9 years or a new primary?‏ ‎‡9 1‏
919 ‎‡a completepathologicalresponseispredictiveforclinicaloutcomeaftertrimodalitytherapyforcarcinomasofthesuperiorpulmonarysulcus‏ ‎‡A Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus‏ ‎‡9 1‏
919 ‎‡a absolutequantificationofdocetaxelkineticsinlungcancerpatientsusingpositronemissiontomography‏ ‎‡A Absolute Quantification of [11C]docetaxel Kinetics in Lung Cancer Patients Using Positron Emission Tomography‏ ‎‡9 1‏
919 ‎‡a costutilityofsteppedcaretargetingpsychologicaldistressinpatientswithheadandneckorlungcancer‏ ‎‡A Cost-Utility of Stepped Care Targeting Psychological Distress in Patients With Head and Neck or Lung Cancer.‏ ‎‡9 1‏
919 ‎‡a multicenterphase2studyoferlotinibandsorafenibinchemotherapynaivepatientswithadvancednonsmallcelllungcancer‏ ‎‡A A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer‏ ‎‡9 1‏
919 ‎‡a detectingresistanceinegfrmutatednonsmallcelllungcancerafterclonalselectionthroughtargetedtherapy‏ ‎‡A Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy.‏ ‎‡9 1‏
919 ‎‡a developmentoferlotinibpositronemissiontomographyforinvivoevaluationofegfreceptormutationalstatus‏ ‎‡A Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.‏ ‎‡9 1‏
919 ‎‡a dnacopynumberaberrationsinendobronchiallesionsavalidatedpredictorforcancer‏ ‎‡A DNA copy number aberrations in endobronchial lesions: a validated predictor for cancer‏ ‎‡9 1‏
919 ‎‡a dramaticresponsetolowdoseerlotinibofepidermalgrowthfactorreceptormutationpositiverecurrentnonsmallcelllungcancerafterseverecutaneoustoxicity‏ ‎‡A Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity‏ ‎‡9 1‏
919 ‎‡a earlypredictionofnonprogressioninadvancednonsmallcelllungcancertreatedwitherlotinibbyusing‏ ‎‡A Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [‏ ‎‡9 1‏
919 ‎‡a earlypredictionofnonprogressioninadvancednonsmallcelllungcancertreatedwitherlotinibbyusingfluorodeoxyglucoseandfluorothymidinepositronemissiontomography‏ ‎‡A Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.‏ ‎‡9 1‏
919 ‎‡a effectsoferlotinibtherapyonerlotinibuptakeinegfrmutatedadvancednsclc‏ ‎‡A Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC.‏ ‎‡9 1‏
919 ‎‡a egfrmutationanalysisinsputumoflungcancerpatientsamultitechniquestudy‏ ‎‡A EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study‏ ‎‡9 1‏
919 ‎‡a evaluationofacumulativesuvvolumehistogrammethodforparameterizingheterogeneousintratumouralfdguptakeinnonsmallcelllungcancerpetstudies‏ ‎‡A Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies‏ ‎‡9 1‏
919 ‎‡a generationoftumorreactivetcellsbycocultureofperipheralbloodlymphocytesandtumororganoids‏ ‎‡A Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids‏ ‎‡9 1‏
919 ‎‡a isthecurrentdiagnosticalgorithmreliableforselectingcasesforegfrandkrasmutationanalysisinlungcancer‏ ‎‡A Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?‏ ‎‡9 1‏
919 ‎‡a longtermexpandinghumanairwayorganoidsfordiseasemodeling‏ ‎‡A Long-term expanding human airway organoids for disease modeling‏ ‎‡9 1‏
919 ‎‡a measuringresponsetotherapyusingfdgpetsemiquantitativeandfullkineticanalysis‏ ‎‡A Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis‏ ‎‡9 1‏
919 ‎‡a methodologicalconsiderationsinquantificationof3deoxy3fluorothymidineuptakemeasuredwithpositronemissiontomographyinpatientswithnonsmallcelllungcancer‏ ‎‡A Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer‏ ‎‡9 1‏
919 ‎‡a negativenkx21‏ ‎‡A Negative NKX2-1‏ ‎‡9 1‏
919 ‎‡a negativenkx21ttf1astemporarysurrogatemarkerfortreatmentselectionduringegfrmutationanalysisinpatientswithnonsmallcelllungcancer‏ ‎‡A Negative NKX2-1 (TTF-1) as Temporary Surrogate Marker for Treatment Selection During EGFR-Mutation Analysis in Patients with Non–Small-Cell Lung Cancer‏ ‎‡9 1‏
919 ‎‡a parametricmethodsforquantificationof18ffazakineticsinnonsmallcelllungcancerpatients‏ ‎‡A Parametric methods for quantification of 18F-FAZA kinetics in non-small cell lung cancer patients‏ ‎‡9 1‏
919 ‎‡a pharmacokineticanalysisoffazainnonsmallcelllungcancerpatients‏ ‎‡A Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients.‏ ‎‡9 1‏
919 ‎‡a prolongedsamplingofspontaneoussputumimprovessensitivityofhypermethylationanalysisforlungcancer‏ ‎‡A Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer.‏ ‎‡9 1‏
919 ‎‡a proteomeanalysisofnonsmallcelllungcancercelllinesecretomesandpatientsputumrevealsbiofluidbiomarkercandidatesforcisplatinresponseprediction‏ ‎‡A Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction‏ ‎‡9 1‏
919 ‎‡a quantitativeandsimplifiedanalysisof11cerlotinibstudies‏ ‎‡A Quantitative and Simplified Analysis of 11C-Erlotinib Studies‏ ‎‡9 1‏
919 ‎‡a rapiddecreaseindeliveryofchemotherapytotumorsafterantivegftherapyimplicationsforschedulingofantiangiogenicdrugs‏ ‎‡A Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.‏ ‎‡9 1‏
919 ‎‡a reproducibilityofquantitative18f3deoxy3fluorothymidinemeasurementsusingpositronemissiontomography‏ ‎‡A Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography‏ ‎‡9 1‏
919 ‎‡a reproducibilityoftumorperfusionmeasurementsusing15olabeledwaterandpet‏ ‎‡A Reproducibility of tumor perfusion measurements using 15O-labeled water and PET.‏ ‎‡9 1‏
919 ‎‡a sorafenibinpatientswithadvancednonsmallcelllungcancerthatharborkrasmutationsabriefreport‏ ‎‡A Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report‏ ‎‡9 1‏
919 ‎‡a steppedcaretargetingpsychologicaldistressinheadandneckandlungcancerpatientsarandomizedclinicaltrial‏ ‎‡A Stepped care targeting psychological distress in head and neck and lung cancer patients: a randomized clinical trial‏ ‎‡9 1‏
919 ‎‡a steppedcaretargetingpsychologicaldistressinheadandneckcancerandlungcancerpatientswhichgroupsspecificallybenefitsecondaryanalysesofarandomizedcontrolledtrial‏ ‎‡A Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: which groups specifically benefit? Secondary analyses of a randomized controlled trial‏ ‎‡9 1‏
919 ‎‡a towardpredictionofefficacyofchemotherapyaproofofconceptstudyinlungcancerpatientsusingdocetaxelandpositronemissiontomography‏ ‎‡A Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography.‏ ‎‡9 1‏
919 ‎‡a assessmentofsimplifiedmethodstomeasure18ffltuptakechangesinegfrmutatednonsmallcelllungcancerpatientsundergoingegfrtyrosinekinaseinhibitortreatment‏ ‎‡A Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.‏ ‎‡9 1‏
919 ‎‡a biodistributionandradiationdosimetryof11clabelleddocetaxelincancerpatients‏ ‎‡A Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients‏ ‎‡9 1‏
919 ‎‡a analysisofaktanderk12proteinkinasesinextracellularvesiclesisolatedfrombloodofpatientswithcancer‏ ‎‡A Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer.‏ ‎‡9 1‏
996 ‎‡2 ISNI|0000000392789522‏
996 ‎‡2 NTA|06761731X‏
996 ‎‡2 NTA|067618235‏
996 ‎‡2 BIBSYS|1581514963749‏
996 ‎‡2 ISNI|0000000398583859‏
996 ‎‡2 NTA|075235455‏
996 ‎‡2 NTA|071995331‏
996 ‎‡2 NTA|067548199‏
996 ‎‡2 NTA|314618848‏
996 ‎‡2 ISNI|0000000393457642‏
996 ‎‡2 DNB|170482553‏
996 ‎‡2 CAOONL|ncf10978126‏
996 ‎‡2 NTA|074610309‏
996 ‎‡2 NTA|296555452‏
996 ‎‡2 NTA|338808043‏
996 ‎‡2 NTA|170102505‏
996 ‎‡2 ISNI|0000000391794549‏
996 ‎‡2 NTA|152869980‏
996 ‎‡2 NTA|070450854‏
996 ‎‡2 NTA|320920356‏
996 ‎‡2 J9U|987007461800305171‏
996 ‎‡2 BAV|495_148348‏
996 ‎‡2 LC|no 98119861‏
996 ‎‡2 DNB|1300981792‏
996 ‎‡2 NTA|074974831‏
996 ‎‡2 ISNI|0000000391831258‏
996 ‎‡2 BNF|14643674‏
996 ‎‡2 NII|DA16554282‏
996 ‎‡2 NTA|344691578‏
996 ‎‡2 NUKAT|n 2006128089‏
996 ‎‡2 ISNI|0000000393907455‏
996 ‎‡2 NTA|116656158‏
996 ‎‡2 LC|n 86872860‏
996 ‎‡2 NTA|074832719‏
996 ‎‡2 NTA|069136408‏
996 ‎‡2 ISNI|0000000387450495‏
996 ‎‡2 J9U|987007455187705171‏
996 ‎‡2 LC|no2010136276‏
996 ‎‡2 NTA|29635967X‏
996 ‎‡2 ISNI|0000000390351842‏
996 ‎‡2 JPG|500026847‏
996 ‎‡2 NTA|239649257‏
996 ‎‡2 LC|no2011078595‏
996 ‎‡2 NTA|418098778‏
996 ‎‡2 ISNI|0000000396002926‏
996 ‎‡2 ISNI|0000000425673121‏
996 ‎‡2 LC|n 00002602‏
996 ‎‡2 ISNI|0000000119749212‏
996 ‎‡2 ISNI|0000000390689800‏
996 ‎‡2 DNB|1075813913‏
996 ‎‡2 SUDOC|169176606‏
996 ‎‡2 NTA|337908249‏
996 ‎‡2 NTA|182139247‏
996 ‎‡2 ISNI|0000000046027672‏
996 ‎‡2 SUDOC|139188533‏
996 ‎‡2 NTA|071469060‏
996 ‎‡2 LC|n 2014022609‏
996 ‎‡2 ISNI|000000039451168X‏
996 ‎‡2 ISNI|0000000387256940‏
996 ‎‡2 NTA|072637595‏
996 ‎‡2 NTA|073553301‏
996 ‎‡2 ISNI|0000000027212709‏
996 ‎‡2 ISNI|0000000390622331‏
996 ‎‡2 ISNI|0000000110382266‏
996 ‎‡2 NUKAT|n 2023150790‏
996 ‎‡2 ISNI|0000000388671708‏
996 ‎‡2 NTA|337395500‏
996 ‎‡2 J9U|987007405550205171‏
996 ‎‡2 ISNI|0000000117943118‏
996 ‎‡2 NTA|416329616‏
996 ‎‡2 NTA|313957428‏
996 ‎‡2 NTA|327783249‏
996 ‎‡2 NTA|074851292‏
996 ‎‡2 ISNI|000000038784315X‏
996 ‎‡2 NTA|162460708‏
996 ‎‡2 NTA|074440705‏
996 ‎‡2 ISNI|0000000395606330‏
996 ‎‡2 ISNI|0000000395767783‏
996 ‎‡2 CAOONL|ncf11331629‏
996 ‎‡2 NTA|430508751‏
996 ‎‡2 DNB|1123048355‏
996 ‎‡2 DNB|173065244‏
996 ‎‡2 NTA|364156082‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏